Bancroft Fund Ltd. Announces Corrected Earnings

MORRISTOWN, NJ -- (Marketwired) -- 06/01/15 -- Bancroft Fund Ltd. (NYSE MKT: BCV) today reported corrected earnings for the six months ended April 30, 2015:

EARNINGS REPORT                                    Six Months Ended
                                                       April 30
                                          ----------------------------------

                                                       2015             2014

Net Income for Six Months                          $398,000         $545,000
  Per Share                                           $0.08            $0.10
Shares Outstanding                                5,131,256        5,242,291
Total Net Assets                               $124,620,000     $121,895,000
Net Asset Value Per Share                            $24.29           $23.25

Data is unaudited and as of April 30, 2015. This select information should be read in conjunction with the financial statements and notes included in the Company's Annual Report to Shareholders for the twelve months ended October 31, 2014.

Detailed portfolio information is available on our website (www.bancroftfund.com). Contact us by email at [email protected] or call us at (973) 631-1177.

Bancroft Fund Ltd. operates as a closed-end, diversified management investment company and invests primarily in convertible securities, with the objectives of providing income and the potential for capital appreciation; which objectives the Fund considers to be relatively equal, over the long-term, due to the nature of the securities in which it invests.

Its shares are traded on the NYSE MKT LLC exchange under the ticker symbol BCV.

Cusip 059695106

For further information please contact:
Gary I. Levine
Chief Financial Officer
Ph. (973) 631-1177
Fax (973) 631-9893
[email protected]
www.bancroftfund.com

Source: Bancroft Fund Ltd.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Vivos Therapeutics posts 35% revenue gain but widens net loss